Table 1.
Frequency of aGVHD response groups by demographic subset of patients with aGVHD
| Frequency | ||||
|---|---|---|---|---|
| Factor | n | Sensitive aGVHD | Dependent aGVHD | Resistant aGVHD |
| Overall | 385 | 114 (30) | 103 (27) | 168 (43) |
| Sex | ||||
| Male | 242 | 71 (29) | 65 (27) | 106 (44) |
| Female | 143 | 43 (30) | 38 (27) | 62 (43) |
| Age, y | ||||
| <18 | 67 | 28 (42) | 10 (15) | 29 (43) |
| 18-40 | 83 | 21 (25) | 29 (35) | 33 (40) |
| 41-60 | 145 | 42 (29) | 45 (31) | 58 (40) |
| 61+ | 48 | 23 (26) | 19 (21) | 48 (53) |
| Year of transplant | ||||
| 2008-2011 | 158 | 45 (28) | 49 (31) | 64 (41) |
| 2012-2016 | 227 | 69 (30) | 54 (24) | 104 (46) |
| Donor type | ||||
| Sibling match | 112 | 31 (28) | 35 (31) | 46 (41) |
| Haploidentical | 10 | 3 (30) | 3 (30) | 4 (40) |
| URD* | 60 | 11 (18) | 10 (17) | 39 (65) |
| Single/double UCB | 203 | 69 (34) | 55 (27) | 79 (39) |
| Prior autologous transplant | ||||
| No | 357 | 107 (30) | 93 (26) | 157 (44) |
| Yes | 28 | 7 (25) | 10 (36) | 11 (39) |
| Pre-transplant conditioning | ||||
| MAC | 178 | 55 (31) | 50 (28) | 73 (41) |
| RIC | 207 | 59 (29) | 53 (26) | 95 (46) |
| GVHD prophylaxis | ||||
| CsA/MTX | 50 | 19 (38) | 13 (26) | 18 (36) |
| CsA/MMF | 290 | 81 (28) | 84 (29) | 125 (43) |
| Sirolimus/MMF | 3 | 0 | 1 (33) | 2 (67) |
| Other | 42 | 14 (33) | 5 (12) | 23 (55) |
| Diagnosis | ||||
| Aplastic/Fanconi anemia | 11 | 3 (27) | 4 (36) | 4 (36) |
| Other nonmalignant† | 29 | 13 (45) | 4 (14) | 12 (41) |
| ALL | 68 | 23 (34) | 20 (29) | 25 (37) |
| AML | 130 | 38 (29) | 34 (26) | 58 (45) |
| CML/CLL/JCML | 34 | 11 (32) | 8 (24) | 15 (44) |
| MDS | 42 | 9 (21) | 9 (21) | 24 (57) |
| Myeloproliferative disorder | 8 | 1 (13) | 2 (25) | 5 (63) |
| NHL/HL | 36 | 9 (25) | 13 (36) | 14 (39) |
| Multiple myeloma | 18 | 4 (22) | 7 (39) | 7 (39) |
| Other malignancy | 9 | 3 (33) | 2 (22) | 4 (44) |
| DRI | ||||
| Low risk | 47 | 14 (30) | 14 (30) | 19 (40) |
| Intermediate risk | 244 | 67 (27) | 71 (29) | 106 (43) |
| High/very high risk | 54 | 17 (31) | 10 (19) | 27 (50) |
| Nonmalignant | 40 | 16 (40) | 8 (20) | 16 (40) |
| HCT-CI | ||||
| Low risk | 192 | 59 (31) | 54 (28) | 79 (41) |
| Intermediate risk | 95 | 34 (36) | 25 (26) | 36 (38) |
| High risk | 98 | 21 (21) | 24 (24) | 53 (54) |
| Karnofsky performance status | ||||
| <90 | 61 | 18 (30) | 10 (16) | 33 (54) |
| ≥90 | 324 | 96 (30) | 93 (29) | 135 (42) |
| MN GVHD risk (at onset) | ||||
| Standard | 301 | 97 (32) | 83 (28) | 121 (40) |
| High | 84 | 17 (20) | 20 (24) | 47 (56) |
| GVHD grade (at onset) | ||||
| 1 | 42 | 12 (29) | 10 (24) | 20 (48) |
| 2 | 201 | 70 (35) | 59 (29) | 72 (36) |
| 3 | 121 | 31 (26) | 31 (26) | 59 (49) |
| 4 | 21 | 1 (5) | 3 (14) | 17 (81) |
| Length of follow-up among survivors, median mo (range) | 31 (6.5-103.6) | 34.8 (9.2-99.6) | 27 (6.9-101) | |
Frequency data are number of patients (percentage of subgroup), unless otherwise indicated.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CsA, cyclosporine; HL, Hodgkin lymphoma; JCML, juvenile chronic myelogenous leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; MTX, methotrexate; NHL, non-Hodgkin lymphoma.
*
Well-matched, partially matched, and mismatched donors.
†
Hemoglobinopathy, immune deficiency, storage disorder, and epidermolysis bullosa.